{"id":"https://openalex.org/W2149390789","doi":"https://doi.org/10.1177/1352458514530489","title":"Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening","display_name":"Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening","alternate_titles":[],"publication_year":2014,"publication_date":"2014-04-16","ids":{"openalex":"https://openalex.org/W2149390789","doi":"https://doi.org/10.1177/1352458514530489","mag":"2149390789","pmid":"https://pubmed.ncbi.nlm.nih.gov/24740371","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4232315"},"language":"en","primary_location":{"id":"doi:10.1177/1352458514530489","doi":"https://doi.org/10.1177/1352458514530489","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1352458514530489","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/1352458514530489","source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2149390789"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://journals.sagepub.com/doi/pdf/10.1177/1352458514530489","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069811479","display_name":"Glenn A Phillips","orcid":"https://orcid.org/0000-0002-9676-1909","observed_orcids":["https://orcid.org/0000-0002-9676-1909"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Glenn A Phillips","raw_affiliation_strings":["Health Economics and Outcomes Research, Global Market Access, Biogen Idec, 133 Boston Post Road, Weston, MA 02493, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research, Global Market Access, Biogen Idec, 133 Boston Post Road, Weston, MA 02493, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040534308","display_name":"Kathleen W. Wyrwich","orcid":"https://orcid.org/0000-0002-8851-350X","observed_orcids":["https://orcid.org/0000-0002-8851-350X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathleen W Wyrwich","raw_affiliation_strings":["Evidera, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, Bethesda, MD, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103525500","display_name":"Shien Guo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shien Guo","raw_affiliation_strings":["Evidera, Lexington, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, Lexington, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112106694","display_name":"Rossella Medori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rossella Medori","raw_affiliation_strings":["Biogen Idec, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024974445","display_name":"Arman Altincatal","orcid":"https://orcid.org/0009-0003-6666-6227","observed_orcids":["https://orcid.org/0009-0003-6666-6227"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arman Altincatal","raw_affiliation_strings":["Evidera, Lexington, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, Lexington, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031490069","display_name":"Linda D. Wagner","orcid":"https://orcid.org/0000-0001-5482-8434","observed_orcids":["https://orcid.org/0000-0001-5482-8434"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Linda Wagner","raw_affiliation_strings":["Envision Pharma Group, Southport, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Envision Pharma Group, Southport, CT, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108457840","display_name":"Jacob S Elkins","orcid":"https://orcid.org/0009-0000-5898-8937","observed_orcids":["https://orcid.org/0009-0000-5898-8937"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob Elkins","raw_affiliation_strings":["Biogen Idec, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5069811479"],"corresponding_institution_ids":["https://openalex.org/I1297540436"],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":{"value":4400,"currency":"USD","value_usd":4400},"fwci":3.3007,"has_fulltext":true,"cited_by_count":63,"citation_normalized_percentile":{"value":0.91625695,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"20","issue":"13","first_page":"1753","last_page":"1760"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10467","display_name":"Psychometric Methodologies and Testing","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1803","display_name":"Management Science and Operations Research"},"field":{"id":"https://openalex.org/fields/18","display_name":"Decision Sciences"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/responder-definition","display_name":"responder definition","score":0.8040000200271606},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.9829999804496765},{"id":"https://openalex.org/keywords/daclizumab","display_name":"daclizumab","score":0.8730000257492065},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.7369999885559082},{"id":"https://openalex.org/keywords/expanded-disability-status-scale","display_name":"Expanded Disability Status Scale","score":0.9459999799728394},{"id":"https://openalex.org/keywords/anchor-based-thresholds","display_name":"anchor-based thresholds","score":0.5669999718666077},{"id":"https://openalex.org/keywords/clinical-trial-endpoints","display_name":"clinical trial endpoints","score":0.5270000100135803}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.8322793841362},{"id":"https://openalex.org/C2780892749","wikidata":"https://www.wikidata.org/wiki/Q929518","display_name":"Expanded Disability Status Scale","level":3,"score":0.7578041553497314},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.5656982660293579},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48804986476898193},{"id":"https://openalex.org/C2779625216","wikidata":"https://www.wikidata.org/wiki/Q1179623","display_name":"Physical disability","level":2,"score":0.41748926043510437},{"id":"https://openalex.org/C99508421","wikidata":"https://www.wikidata.org/wiki/Q2678675","display_name":"Physical medicine and rehabilitation","level":1,"score":0.3514936566352844},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3491564393043518},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.11690056324005127}],"mesh":[{"descriptor_ui":"D000077561","descriptor_name":"Daclizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004185","descriptor_name":"Disability Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D057566","descriptor_name":"Self Report","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1177/1352458514530489","doi":"https://doi.org/10.1177/1352458514530489","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1352458514530489","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/1352458514530489","source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4232315","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4232315/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4232315/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Mult Scler","raw_type":"Text"},{"id":"pmh:oai:europepmc.org:3205762","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4232315","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:24740371","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24740371","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple sclerosis (Houndmills, Basingstoke, England)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1177/1352458514530489","doi":"https://doi.org/10.1177/1352458514530489","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1352458514530489","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/1352458514530489","source":{"id":"https://openalex.org/S136332993","display_name":"Multiple Sclerosis Journal","issn_l":"1352-4585","issn":["1352-4585","1477-0970"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320308604","display_name":"Biogen","ror":"https://ror.org/02jqkb192"},{"id":"https://openalex.org/F4320333023","display_name":"AbbVie Biotherapeutics","ror":"https://ror.org/03a0g6939"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2149390789.pdf","grobid_xml":"https://content.openalex.org/works/W2149390789.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W1522708125","https://openalex.org/W1964685529","https://openalex.org/W1966752139","https://openalex.org/W1967126262","https://openalex.org/W1973185874","https://openalex.org/W1977733462","https://openalex.org/W1995110505","https://openalex.org/W2006994284","https://openalex.org/W2007711722","https://openalex.org/W2012878102","https://openalex.org/W2066212948","https://openalex.org/W2083550634","https://openalex.org/W2094993869","https://openalex.org/W2095263941","https://openalex.org/W2099716808","https://openalex.org/W2110624941","https://openalex.org/W2112165124","https://openalex.org/W2115447875","https://openalex.org/W2116264620","https://openalex.org/W2126737632","https://openalex.org/W2137446015","https://openalex.org/W2140546155","https://openalex.org/W2152536194","https://openalex.org/W2153061458","https://openalex.org/W2155077612","https://openalex.org/W2158690309","https://openalex.org/W2167414238","https://openalex.org/W2171419938","https://openalex.org/W2172151487","https://openalex.org/W2316494973"],"related_works":["https://openalex.org/W2614085198","https://openalex.org/W2905955079","https://openalex.org/W2095263941","https://openalex.org/W2045596513","https://openalex.org/W2110624941","https://openalex.org/W2531923206","https://openalex.org/W2126737632","https://openalex.org/W2066212948","https://openalex.org/W2116264620","https://openalex.org/W4387125885"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1],"29-item":[2],"Multiple":[3],"Sclerosis":[4],"Impact":[5],"Scale":[6,89],"(MSIS-29)":[7],"was":[8,75,135],"developed":[9],"to":[10,97,129],"examine":[11],"the":[12,30,35,58,85,102,107,138,150,166,188],"impact":[13,38,190],"of":[14,34,44,115,133,154,191],"multiple":[15],"sclerosis":[16],"(MS)":[17],"on":[18,146,165],"physical":[19,37,143,189],"and":[20,84,92,120,172],"psychological":[21],"functioning":[22],"from":[23,57,127],"a":[24,42,52,161,170,183],"patient's":[25],"perspective.":[26],"OBJECTIVE:":[27],"To":[28],"determine":[29],"responder":[31],"definition":[32],"(RD)":[33],"MSIS-29":[36,111,167],"subscale":[39],"(PHYS)":[40],"in":[41,51,67,77,149,187],"group":[43],"patients":[45,68,177],"with":[46,65,69,178],"relapsing-remitting":[47],"MS":[48],"(RRMS)":[49],"participating":[50],"clinical":[53],"trial.":[54],"METHODS:":[55],"Data":[56],"SELECT":[59,78],"trial":[60],"comparing":[61],"daclizumab":[62],"high-yield":[63],"process":[64],"placebo":[66],"RRMS":[70,179],"were":[71,95],"used.":[72],"Physical":[73],"function":[74],"evaluated":[76],"using":[79],"three":[80],"patient-reported":[81],"outcomes":[82],"measures":[83],"Expanded":[86],"Disability":[87],"Status":[88],"(EDSS).":[90],"Anchor-":[91],"distribution-based":[93],"methods":[94],"used":[96],"identify":[98],"an":[99],"RD":[100,113,124,132],"for":[101,142,175],"MSIS-29.":[103],"RESULTS:":[104],"Results":[105],"across":[106],"anchor-based":[108],"approach":[109],"suggested":[110],"PHYS":[112,168],"values":[114],"6.91":[116],"(mean),":[117],"7.14":[118],"(median)":[119],"7.50":[121,134],"(mode).":[122],"Distribution-based":[123],"estimates":[125],"ranged":[126],"6.24":[128],"10.40.":[130],"An":[131],"selected":[136],"as":[137],"most":[139],"appropriate":[140],"threshold":[141,174],"worsening":[144,164],"based":[145],"corresponding":[147],"changes":[148],"EDSS":[151],"(primary":[152],"anchor":[153],"interest).":[155],"CONCLUSION:":[156],"These":[157],"findings":[158],"indicate":[159],"that":[160],"\u22657.50":[162],"point":[163],"is":[169],"reasonable":[171],"practical":[173],"identifying":[176],"who":[180],"have":[181],"experienced":[182],"clinically":[184],"significant":[185],"change":[186],"MS.":[192]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2149390789","counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":5}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
